Allison Dorval Sells Shares of PBYI
PBYI insider Allison Dorval sold shares worth $83,592 on June 12, 2026.
Key Points
- Allison Dorval sold 11,610 shares of PBYI at $7.20 each, totaling $83,592, in a planned transaction on June 12, 2026.
- Shares of PBYI traded around $7.33, with insider sales involving several executives on the same day.
- HC Wainwright & Co. reiterated a 'buy' rating with a $7.00 target, while other firms hold varied views on PBYI.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 12, 2026, Allison Dorval sold 11,610 shares of PBYI at an average price of $7.20 per share. This planned transaction was valued at $83,592. Dorval's sale is part of a series of insider activities on the same day, highlighting ongoing transactions within the company.
Insider Buying and Selling at Puma Biotechnology, Inc.
In addition to Allison Dorval's sale, several other PBYI insiders were active on June 12, 2026. Brian Stuglik sold 8,100 shares, Adrian Senderowicz offloaded 27,000 shares, and Troy Edward Wilson sold 10,800 shares, all at $7.20 per share in planned transactions. Jay Moyes sold 22,000 shares at $7.22 per share and also purchased 27,000 shares a day earlier on June 11, 2026, in an unplanned transaction.
Other Institutional Activity in PBYI
Institutional investors have shown mixed activity in PBYI. BlackRock, Inc. reduced its holdings by 43,636 shares, bringing its total to 3,598,952 shares valued at approximately $22.99 million. Meanwhile, American Century Companies Inc. increased its stake significantly by 266,209 shares, ending with 1,916,346 shares worth about $12.25 million. Renaissance Technologies LLC also cut its position by 181,400 shares, holding 1,942,413 shares valued at $12.41 million.
Analysts Set New Price Targets
Analysts have varied opinions on PBYI. HC Wainwright & Co. reiterated its 'buy' rating with a target price of $7.00 on February 28, 2025. TD Cowen maintained a 'hold' rating with a $4.00 target on May 20, 2024, while Barclays maintained a 'sell' rating with a $2.00 target on May 3, 2024. The consensus among analysts shows a mixed outlook with varying target prices.
Bottom Line
Insider sales at PBYI, including Allison Dorval's planned transaction, coincide with a broader pattern of insider activity. Institutional investors have shown both interest and caution, reflected in their varied trading actions. Analysts also present a mixed view on PBYI's future, with price targets ranging from $2.00 to $7.00. As always, it's essential to remember that these insights are backward-looking and reflect filings and transactions made prior to the current date.
Get Puma Biotechnology, Inc. alerts
New 13F filings, insider trades, and analyst moves on $PBYI, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.